Choose your preferred way to stay informed of new case launches and settlement deadlines
On August 19, 2024, Liquidia shares have dropped 35% following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug treating adults with pulmonary diseases. The delay has been referred to as a "curveball scenario" by Needham, as the drug was expected to be approved for launch by 4Q24.
In order to be eligible to join the LQDA class action lawsuit, you must have incurred a loss on shares of Liquidia Corporation purchased during the class period listed above.
TOP
